Completed NA INTERVENTIONAL 1-arm NCT00640289

Clinical Trial of Factor XIII (FXIII) Concentrate

Clinical Research Study of Factor XIII Concentrate From Human Plasma Fibrogammin P in Patients With Factor XIII Deficiency

Sponsor: CSL Behring

Conditions Factor XIII Deficiency Hemophilia

Interventions Fibrogammin P

Updated 8 times since 2017 Last updated: Oct 11, 2018 Started: Jan 31, 2000 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00640289, this NA trial focuses on Factor XIII Deficiency and Hemophilia and remains completed. Sponsored by CSL Behring, it has been updated 8 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Sep 2020 — Jan 2021 [monthly]

Completed NA
Dec 2018 — Sep 2020 [monthly]

Completed NA

▶ Show 3 earlier versions

Jun 2018 — Dec 2018 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Jan 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring
Children's Hospital of Orange County

Data source: Children's Hospital of Orange County

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orange, United States